🇺🇸 FDA
Patent

US 9771366

Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors

granted A61KA61K31/337A61K31/4355

Quick answer

US patent 9771366 (Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors) held by PHOENIX MOLECULAR DESIGNS expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PHOENIX MOLECULAR DESIGNS
Grant date
Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/337, A61K31/4355, A61K31/437, A61K31/496